RA Capital's large stake is a strong vote of confidence in IKT's pipeline and prospects. Traders should watch for a potential Schedule 13D filing to clarify investment intent, and monitor for any related stock purchases or strategic moves by the fund.
Price Chart
Executive Summary
RA Capital Healthcare Fund LP and affiliated entities (RA Capital Management, Peter Kolchinsky, Rajeev Shah) filed initial Form 3 ownership statements disclosing a 25,000,000 share common stock position in Inhibikase Therapeutics (IKT). This represents a substantial stake in the $265M market cap biotech, signaling strong conviction from a highly regarded healthcare-focused investment firm.
Key Facts
- RA Capital Healthcare Fund LP directly holds 25,000,000 shares of IKT common stock.
- RA Capital Management L.P. serves as the investment manager, and Peter Kolchinsky and Rajeev Shah are the managing members of the general partner.
- The filing is an initial statement of beneficial ownership (Form 3), indicating RA Capital likely crossed the 10% ownership threshold.
- The stake is valued at a significant portion of IKT's $265M market cap, implying a meaningful ownership percentage.
Financial Impact
25,000,000 shares of common stock owned; no dollar value disclosed, but at IKT's current market cap this represents a substantial percentage of the company.
Risk Factors
- Form 3 does not disclose intent; the fund could reduce its position in the future.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (IKT) — Batch item 1 | 0001231919-26-000769 |
| Document: 0001231919-26-000769-index.html | 0001231919-26-000769 |
| Document: 0001231919-26-000769.txt | 0001231919-26-000769 |
| 3 Filing (IKT) — Batch item 4 | 0001231919-26-000769 |
| Document: 0001231919-26-000769-index.html | 0001231919-26-000769 |
| Document: 0001231919-26-000769.txt | 0001231919-26-000769 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.66 | awaiting T+20 | — | $1.57 (−5.42%) |
Oct 2, 2026 25d ago | Press Release | $2.00 | awaiting T+20 | — | $1.57 (−21.50%) |
Aug 11, 2026 11w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.57 (−34.58%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.57 (−32.62%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.57 (−29.60%) |
Jul 14, 2026 15w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.57 (+23.79%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.57 (−18.65%) |
May 12, 2026 24w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
May 12, 2026 24w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
Apr 7, 2026 29w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.57 (−10.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers